|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread
2
Measles Update: November 6, 2026
3
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
4
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
5